

07 August 2025

To National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Scrip Symbol: SaiLife	To BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai - 400001 BSE Scrip Code: 544306
---	--

Sub: Outcome of the Board Meeting dated 07 August 2025.

Dear Sir/ Madam,

Pursuant to Regulation 30, 33 and any other provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that, the Board of Directors of the Company, at its meeting held on Thursday, 07 August 2025, inter-alia considered and approved the following:

1. Unaudited Financial Results (Standalone and Consolidated) of the Company and noted the Limited Review Report of the Statutory Auditors, M/s. Deloitte Haskins & Sells LLP for the quarter ended on 30 June 2025. A copy of the same are enclosed herewith as **Annexure-I**.
2. Reappointment of Mr. Krishnamraju Kanumuri (DIN: 00064614) Managing Director & CEO as Managing Director & CEO of the Company for a term of 5 years effective from 01 September 2025, subject to approval of the members of the Company at the ensuing Annual General Meeting.
3. The 26th Annual General Meeting of the Company will be held on Thursday, 11 September 2025 at 10:30 AM (IST) through Video Conferencing / Other Audio-Visual Means.

The Meeting of the Board of Directors was duly commenced at 06:30 PM (IST) and concluded at 09:29 PM (IST).

We request you to take note of the same and oblige.

Thank you.

For Sai Life Sciences Limited

Runa Karan
Company Secretary & Compliance Officer
Membership No.: A13721

Encl: As above

Sai Life Sciences Limited (CIN: L24110TG1999PLC030970)

Corporate office

L4-01 & 02, SLN Terminus, Survey
#133, Gachibowli Miyapur Road,
Gachibowli, Hyderabad – 500032,
Telangana, India.

Registered office

Plot No. DS-7, IKP Knowledge Park, Turkapally
(V), Shameerpet Mandal, Medchal-Malkajgiri
(Dist), Hyderabad -500078, Telangana, India.

Contact us

T: +91 40 6815 6000,
F: +91 40 6815 6199
E: info@sailife.com
W: www.sailife.com

SAI LIFE SCIENCES LIMITED

CIN: L24110TG1999PLC030970 | Website: www.sailife.com

Registered Office: DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajgiri District-500078, Telangana, India

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025

(Rs. in million, except per share data)

Sl.No	Particulars	Quarter Ended			Year Ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Unaudited (Refer Note 3)	Unaudited (Refer Note 3)	Audited
	INCOME				
I	Revenue from operations	4,830.38	5,670.06	2,644.69	16,420.48
II	Other income	100.06	98.19	81.15	373.35
III	Total income (I + II)	4,930.44	5,768.25	2,725.84	16,793.83
IV	EXPENSES				
	Cost of material, chemicals & reagents consumed	1,553.31	1,540.63	807.30	4,455.19
	Changes in inventories of work-in-progress	(181.48)	103.34	(120.91)	41.30
	Employee benefits expense	1,425.85	1,345.46	1,123.57	4,855.57
	Finance costs	106.96	91.58	197.68	700.32
	Depreciation and amortisation expense	343.25	340.95	280.93	1,260.33
	Other expenses	902.73	1,141.64	588.83	3,163.96
	Total expenses (IV)	4,150.62	4,563.60	2,877.40	14,476.67
V	Profit/(loss) before tax (III - IV)	779.82	1,204.65	(151.56)	2,317.16
VI	Tax expense				
	(i) Current tax	138.57	175.29	-	338.16
	(ii) Deferred tax	57.55	130.01	(37.77)	244.38
	Total tax expense (VI)	196.12	305.30	(37.77)	582.54
VII	Profit/(loss) for the period / year (V - VI)	583.70	899.35	(113.79)	1,734.62
VIII	Other comprehensive income:				
A.	Items that will not be reclassified to profit or loss:				
	(i) Re-measurement of defined benefit plans	(0.57)	12.96	(2.81)	4.53
	(ii) Income-tax on items that will not be reclassified to profit or loss	0.14	(3.26)	0.70	(1.14)
B.	Items that will be reclassified to profit or loss:				
	(i) Effective portion of gain/(loss) on designated portion of hedging instruments in a cash flow hedge	20.54	84.69	44.06	7.70
	(ii) Income-tax on items that will be reclassified to profit or loss	(5.17)	(21.31)	(11.09)	(1.94)
	Total other comprehensive income for the period / year, net of tax (A + B)	14.94	73.08	30.86	9.15
	Total comprehensive income/(loss) for the period / year (VII + VIII)	598.64	972.43	(82.93)	1,743.77
IX	Paid-Up Equity share capital	208.55	208.41	181.29	208.41
	Other equity				21,466.23
	Earnings per equity share	Not Annualised	Not Annualised	Not Annualised	Annualised
	a) Basic	2.80	4.32	(0.63)	9.00
	b) Diluted	2.73	4.22	(0.63)	8.78

See accompanying notes to the standalone financial results

SAI LIFE SCIENCES LIMITEDCIN: L24110TG1999PLC030970 | Website: www.sailife.com

Registered Office: DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajgiri District-500078, Telangana, India

Notes:

- 1 The above Standalone financial results of Sai Life Sciences Limited ('the Company') for the quarter ended 30 June 2025 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS)- 34 "Interim Financial Results" prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The Standalone financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 07 August 2025. The Standalone financial results for the quarter ended 30 June 2025 have been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended 30 June 2025.
- 3 The comparative financial results for the quarter ended 31 March 2025 are balancing figures between the audited figures in respect of the financial year ended 31 March 2025 and the published unaudited year to date figures for the nine months ended 31 December 2024 which were subjected to limited review by the statutory auditors of the Company. The comparative financial results for the quarter ended 30 June 2024 are presented solely based on the information compiled by the management in accordance with the recognition and measurement principles laid down in the Ind AS-34 and have not been reviewed by the statutory auditors. However, the management has exercised necessary diligence in preparing of the financial results of this period.
- 4 During the previous year ended 31 March 2025, the Company has completed its Initial Public Offer of equity shares of face value of Rs. 1 each at a issue price of Rs. 549 per share (including premium of Rs. 548 per share) comprising of Offer for Sale of 38,116,934 equity shares by selling share holders aggregating to Rs. 20,962.19 million and fresh issue of 17,304,189 equity shares aggregating to Rs. 9,500.00 million. The equity shares of the Company got listed on National Stock Exchange of India Limited and Bombay Stock Exchange on 18 December 2024.

The total offer expenses are estimated to be Rs. 1,284.81 million (inclusive of taxes) which are proportionately allocated between the selling shareholders and the Company in the ratio of equity shares sold by the selling shareholders and issued by the Company. The utilisation of IPO proceeds of Rs. 9,098.84 million (net of provisional IPO expenses of Rs. 401.16 million) is summarized below:

(Rs. in million)			
Objects of the offer as per Prospectus	Amount to be Utilised	Utilisation up to 30 June 2025	Unutilised as at 30 June 2025*
Repayment / prepayment, in full or part of all or certain outstanding borrowings availed by our company	7,200.00	7,200.00	-
General corporate purposes	1,898.84	935.78	963.06
Total	9,098.84	8,135.78	963.06

* Net proceeds which were unutilised as at 30 June 2025 are temporarily invested in short-term deposits with a scheduled commercial bank.

For and on behalf of Board of Directors
Sai Life Sciences Limited

Krishnam Raju
Managing Director
DIN No: 00064614

Place : Hyderabad
Date : 07 August 2025

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SAI LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Sai Life Sciences Limited ("the Company"), for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. As stated in Note 3 of the Statement, financial information relating to the quarter ended June 30, 2024 prepared in accordance with Ind AS 34, included in the Statement have been furnished to us by the Management and have not been subjected to audit or review by us. Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**

Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Sathya P. Koushik
(Partner)

(Membership No. 206920)
(UDIN: 25206920BMJHKE5645)

Place: Bengaluru
Date: August 07, 2025
SPK/RK/2025

SAI LIFE SCIENCES LIMITED

CIN: L24110TG1999PLC030970 | Website: www.sailife.com

Registered Office: DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajgiri District-500078, Telangana, India

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2025

(Rs. in million, except per share data)

Sl.No	Particulars	Quarter Ended			Year Ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Unaudited (Refer Note 4)	Unaudited (Refer Note 4)	Audited
	INCOME				
I	Revenue from operations	4,964.19	5,795.07	2,797.23	16,945.70
II	Other income	99.04	95.99	81.12	367.79
III	Total income (I + II)	5,063.23	5,891.06	2,878.35	17,313.49
IV	EXPENSES				
	Cost of material, chemicals & reagents consumed	1,595.04	1,568.71	846.30	4,607.95
	Changes in inventories of work-in-progress	(183.94)	108.52	(114.90)	49.69
	Employee benefits expense	1,606.21	1,510.94	1,303.49	5,491.18
	Finance costs	123.64	108.87	212.20	761.64
	Depreciation and amortisation expense	377.24	374.88	310.74	1,385.73
	Other expenses	737.56	1,031.17	501.17	2,740.27
	Total expenses (IV)	4,255.75	4,703.09	3,059.00	15,036.46
V	Profit/(loss) before tax (III - IV)	807.48	1,187.97	(180.65)	2,277.03
VI	Tax expense				
	(i) Current tax	140.86	175.47	-	338.44
	(ii) Deferred tax	62.07	129.81	(45.67)	237.27
	Total tax expense (VI)	202.93	305.28	(45.67)	575.71
VII	Profit/(loss) for the period / year (V - VI)	604.55	882.69	(134.98)	1,701.32
VIII	Other comprehensive income:				
A.	(i) Items that will not be reclassified to profit or loss:				
	(a) Re-measurement of defined benefit plans	(0.57)	12.75	(2.81)	4.52
	(ii) Income-tax on items that will not be reclassified to profit or loss	0.14	(3.29)	0.71	(1.17)
B.	(i) Items that will be reclassified to profit or loss:				
	(a) Effective portion of gain/(loss) on designated portion of hedging instruments in a cash flow hedge	20.54	84.70	44.06	7.70
	(b) Exchange differences on translating foreign operations	1.21	0.58	(7.09)	2.78
	(ii) Income-tax on items that will be reclassified to profit or loss	(5.17)	(21.32)	(11.10)	(1.94)
	Total other comprehensive income for the period / year, net of tax (A + B)	16.15	73.42	23.77	11.89
	Total comprehensive income/(loss) for the period / year (VII + VIII)	620.70	956.11	(111.21)	1,713.21
	Paid-Up Equity share capital	208.55	208.41	181.29	208.41
	Other equity				21,075.13
IX	Earnings per equity share	Not Annualised	Not Annualised	Not Annualised	Annualised
	a) Basic	2.90	4.24	(0.74)	8.83
	b) Diluted	2.83	4.14	(0.74)	8.61

See accompanying notes to the consolidated financial results

SAI LIFE SCIENCES LIMITED

CIN: L24110TG1999PLC030970 | Website: www.sailife.com

Registered Office: DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajgiri District-500078, Telangana, India

Notes:

- 1 The Consolidated financial results include the financial results of the Parent - Sai Life Sciences Limited and the financial results of the following subsidiaries:
i. Sai Life Sciences Inc, USA
ii. Sai Life GmbH, Germany
iii. Sai Life Pharma Limited, India
The Company and the Subsidiaries are collectively referred to as 'the Group'.
- 2 The above Consolidated financial results of the Group for the quarter ended 30 June 2025 have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS)- 34 "Interim Financial Results" prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 3 The Consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 07 August 2025. The Consolidated financial results for the quarter ended 30 June 2025 have been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended 30 June 2025.
- 4 The comparative financial results for the quarter ended 31 March 2025 are balancing figures between the audited figures in respect of the financial year ended 31 March 2025 and the published unaudited year to date figures for the nine months ended 31 December 2024 which were subjected to limited review by the statutory auditors of the Company. The comparative financial results for the quarter ended 30 June 2024 are presented solely based on the information compiled by the management in accordance with the recognition and measurement principles laid down in the Ind AS-34 and have not been reviewed by the statutory auditors. However, the management has exercised necessary diligence in preparing of the financial results of this period.

5 Information of Standalone financial results:

(Rs. in million)

Particulars	Quarter Ended			Year Ended
	30 June 2025	31 March 2025	30 June 2024	31 March 2025
	Unaudited	Unaudited	Unaudited	Audited
Total Income	4,830.38	5,670.06	2,644.69	16,420.48
Profit/(loss) before tax	779.82	1,204.65	(151.56)	2,317.16
Profit/(loss) after tax	583.70	899.35	(113.79)	1,734.62

- 6 During the previous year ended 31 March 2025, the Company has completed its Initial Public Offer of equity shares of face value of Rs. 1 each at a issue price of Rs. 549 per share (including premium of Rs. 548 per share) comprising of Offer for Sale of 38,116,934 equity shares by selling share holders aggregating to Rs. 20,962.19 million and fresh issue of 17,304,189 equity shares aggregating to Rs. 9,500.00 million. The equity shares of the Company got listed on National Stock Exchange of India limited and Bombay Stock Exchange on 18 December 2024.

The total offer expenses are estimated to be Rs. 1,284.81 million (inclusive of taxes) which are proportionately allocated between the selling shareholders and the Company in the ratio of equity shares sold by the selling shareholders and issued by the Company. The utilisation of IPO proceeds of Rs. 9,098.84 million (net of provisional IPO expenses of Rs. 401.16 million) is summarized below:

(Rs. in million)

Objects of the offer as per Prospectus	Amount to be Utilised	Utilisation up to 30 June 2025	Unutilised as at 30 June 2025*
Repayment / prepayment, in full or part of all or certain outstanding borrowings availed by our company	7,200.00	7,200.00	-
General corporate purposes	1,898.84	935.78	963.06
Total	9,098.84	8,135.78	963.06

* Net proceeds which were unutilised as at 30 June 2025 are temporarily invested in short-term deposits with a scheduled commercial bank.

- 7 The Group operates in a single segment of providing "Contract Research, Development and Manufacturing (CRDMO)". Hence, no separate segment disclosures is required under "Ind AS-108 on Operating Segments".

**For and on behalf of Board of Directors
Sai Life Sciences Limited**

**Place: Hyderabad
Date: 07 August 2025**

**Krishnam Raju
Managing Director
DIN No: 00064614**

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF SAI LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Sai Life Sciences Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sl. No.	Name of the entity	Relationship
1	Sai Life Sciences Limited	Parent
2	Sai Life Pharma Private Limited	Wholly owned Subsidiary
3	Sai Life Sciences Inc.	Wholly owned Subsidiary
4	Sai Life Sciences GMBH	Wholly owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Deloitte Haskins & Sells LLP

6. We did not review the interim financial information of 2 subsidiaries included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 364.72 million for the quarter ended June 30, 2025, total net profit after tax of Rs. 20.67 million for the quarter ended June 30, 2025 and total comprehensive income of Rs. 20.67 million for the quarter ended June 30, 2025, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

7. As stated in Note 4 of the Statement, financial information relating to the quarter ended June 30, 2024 prepared in accordance with Ind AS 34, included in the Statement have been furnished to us by the Management and have not been subjected to audit or review by us. Our conclusion on the statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

Sathya P. Koushik
Partner
(Membership No. 206920)
(UDIN: 25206920BMJHKF5799)

Place: Bengaluru
Date: August 07, 2025
SPK/RK/2025